ZYVERSA THERAPEUTICS, INC. Deferred Federal Income Tax Expense (Benefit)
ZYVERSA THERAPEUTICS, INC. (ZVSA) reported Deferred Federal Income Tax Expense (Benefit) of -$5.06 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Expense Statement › Income Tax
us-gaap:DeferredFederalIncomeTaxExpenseBenefit · last filed 2026-03-31
- ZYVERSA THERAPEUTICS, INC. deferred federal income tax expense (benefit) for fiscal 2025 was -$5.06M.
- ZYVERSA THERAPEUTICS, INC. deferred federal income tax expense (benefit) for fiscal 2024 was -$1.69M.
- ZYVERSA THERAPEUTICS, INC. deferred federal income tax expense (benefit) for fiscal 2023 was -$19.10M.
| Period end | Deferred Federal Income Tax Expense (Benefit) 1 month | Deferred Federal Income Tax Expense (Benefit) 9 month | Deferred Federal Income Tax Expense (Benefit) 11 month | Deferred Federal Income Tax Expense (Benefit) 12 month |
|---|---|---|---|---|
| 2025-12-31 | -$5.06M 10-K · filed 2026-03-31 | |||
| 2024-12-31 | -$1.69M 10-K · filed 2026-03-31 | |||
| 2023-12-31 | -$19.10M 10-K · filed 2025-03-27 | |||
| 2022-12-31 | -$151.63K 10-K · filed 2024-03-25 | |||
| 2022-12-12 | -$2.19M 10-K · filed 2024-03-25 | |||
| 2021-12-31 | -$49.41K 10-K · filed 2022-04-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |